Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | ELANE | P08246 | 2/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.59 |
| ▸ | PLG | P00747 | 1/20 | 0.59 |
| ▸ | CTSG | P08311 | 1/20 | 0.59 |
| ▸ | CMA1 | P23946 | 1/20 | 0.59 |
| ▸ | CTRC | Q99895 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | EP300 | Q09472 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3990677 | 1.00 | MEN1 (1.00) | MEN1KMT2AALDH1A1ELANEF2 | |
| SCHEMBL14189454 | 1.00 | MEN1 (1.00) | MEN1KMT2AALDH1A1ELANEF2 | |
| SCHEMBL2435698 | 1.00 | MEN1 (1.00) | MEN1KMT2AALDH1A1ELANEF2 | |
| SCHEMBL8714088 | 1.00 | MEN1 (1.00) | MEN1KMT2AALDH1A1ELANEF2 | |
| SCHEMBL2435977 | 1.00 | MEN1 (1.00) | MEN1KMT2AALDH1A1ELANEF2 | |
| SCHEMBL7825065 | 0.83 | MEN1 (0.70) | MEN1KMT2AALDH1A1ELANEF2 | |
| SCHEMBL16775234 | 0.83 | KMT2A (0.70) | MEN1KMT2AALDH1A1ELANEF2 | |
| SCHEMBL16759895 | 0.83 | KMT2A (0.70) | MEN1KMT2AALDH1A1ELANEF2 | |
| SCHEMBL22647700 | 0.81 | KMT2A (0.68) | MEN1KMT2AALDH1A1ELANEF2 | |
| SCHEMBL22571107 | 0.81 | KMT2A (0.66) | MEN1KMT2AALDH1A1ELANEF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10835612-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-17 | — | — | US | disclosed |
| EP-3238738-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2020-09-23 | — | — | EP | disclosed |
| US-10544095-B2 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | PFIZER INC. (US) | 2020-01-28 | — | — | US | disclosed |
| EP-3067351-B1 | COMPOUND HAVING HIGHER INHIBITION OF PROTEIN KINASE G ACTIVITY AND PREPARATION METHOD THEREFOR | JENKEM TECH CO LTD TIANJIN (CN) | 2019-02-06 | — | — | EP | disclosed |
| EP-3071570-B1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-3071570-B1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20180125985-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-05-10 | — | — | US | disclosed |
| US-20180125985-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-05-10 | — | — | US | disclosed |
| US-9925171-B2 | Compound having higher inhibitory activity on protein kinase G and preparation method thereof | Jenkem Technology Co., Ltd., (Tianjin) (CN) | 2018-03-27 | — | — | US | disclosed |
| US-20180064807-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-08 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| US-5585500-A | Method of producing optically active pyrrolidines with high enantiomeric purity | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1996-12-17 | — | — | US | disclosed |
| EP-0692471-A1 | Process for the preparation of optically active 3-hydroxypyrrolidine derivatives with high optical purity | Degussa Aktiengesellschaft (DE) | 1996-01-17 | — | — | EP | disclosed |
| EP-0185882-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 1-BENZYL-3,4-BIS-(DIPHENYLPHOSPHINO)-PYRROLIDINE | Degussa Aktiengesellschaft (DE) | 1989-09-13 | — | — | EP | disclosed |
| EP-0151282-B1 | OPTICALLY ACTIVE 3,4-BIS-(DIPHENYLPHOSPHINO)-PYRROLIDINE, RHODIUM COMPLEXES CONTAINING THEM AS CHIRAL LIGANDS, AND THEIR USE | Degussa Aktiengesellschaft (DE) | 1988-09-07 | — | — | EP | disclosed |
| US-4668795-A | Process for the production of optically active 1-benzyl-3,4-bis-(diphenylphosphino)-pyrrolidine | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1987-05-26 | — | — | US | disclosed |
| US-4634775-A | HYDROGENATION CATALYSTS FOR ACYLAMINO-ACRYLIC ACIDS | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1987-01-06 | — | — | US | disclosed |
| EP-0185882-A1 | Process for preparing optically active 1-benzyl-3,4-bis-(diphenylphosphino)-pyrrolidine | Degussa Aktiengesellschaft (DE) | 1986-07-02 | — | — | EP | disclosed |
| EP-0151282-A1 | Optically active 3,4-bis-(diphenylphosphino)-pyrrolidine, rhodium complexes containing them as chiral ligands, and their use | Degussa Aktiengesellschaft (DE) | 1985-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125985-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | MEN1 2422/4885KMT2A 4246/4885ALDH1A1 3880/4885 |
| US-10544095-B2 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | TDO2, IDO1, IDO2 | MEN1 4612/4885KMT2A 3021/4885ALDH1A1 615/4885 |
| US-20180064807-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | MEN1 2333/4885KMT2A 4228/4885ALDH1A1 3847/4885 |
| US-10835612-B2 | Lipids and compositions for the delivery of therapeutics | CETP, LCAT, LIPA | MEN1 1761/4885KMT2A 3847/4885ALDH1A1 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.